JP2017516775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516775A5 JP2017516775A5 JP2016568918A JP2016568918A JP2017516775A5 JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5 JP 2016568918 A JP2016568918 A JP 2016568918A JP 2016568918 A JP2016568918 A JP 2016568918A JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- treatment
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 6
- 230000000340 anti-metabolite Effects 0.000 claims 6
- 229940100197 antimetabolite Drugs 0.000 claims 6
- 239000002256 antimetabolite Substances 0.000 claims 6
- 238000009175 antibody therapy Methods 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MKLKAQMPKHNQPR-NSHDSACASA-N C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O Chemical compound C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O MKLKAQMPKHNQPR-NSHDSACASA-N 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096807A JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462002366P | 2014-05-23 | 2014-05-23 | |
| US62/002,366 | 2014-05-23 | ||
| US201562150004P | 2015-04-20 | 2015-04-20 | |
| US62/150,004 | 2015-04-20 | ||
| PCT/US2015/031931 WO2015179615A1 (en) | 2014-05-23 | 2015-05-21 | Combination therapies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Division JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516775A JP2017516775A (ja) | 2017-06-22 |
| JP2017516775A5 true JP2017516775A5 (OSRAM) | 2018-06-28 |
| JP6787792B2 JP6787792B2 (ja) | 2020-11-18 |
Family
ID=53277114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568918A Active JP6787792B2 (ja) | 2014-05-23 | 2015-05-21 | がんの処置のための併用治療 |
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170182003A1 (OSRAM) |
| EP (2) | EP3134085B1 (OSRAM) |
| JP (2) | JP6787792B2 (OSRAM) |
| KR (1) | KR102535283B1 (OSRAM) |
| CN (2) | CN110354266A (OSRAM) |
| AU (1) | AU2015264102C1 (OSRAM) |
| CA (1) | CA2949961C (OSRAM) |
| IL (1) | IL249065A0 (OSRAM) |
| MA (1) | MA39906A (OSRAM) |
| MX (1) | MX393818B (OSRAM) |
| RU (1) | RU2708374C2 (OSRAM) |
| SG (1) | SG11201609770TA (OSRAM) |
| WO (1) | WO2015179615A1 (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110354266A (zh) * | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2017292522B2 (en) * | 2016-07-07 | 2022-10-13 | Ono Pharmaceutical Co., Ltd. | Combination comprising EP4 antagonist and immune checkpoint inhibitor |
| CN109906088A (zh) | 2016-08-26 | 2019-06-18 | 奥野哲治 | 微血管血流减少剂及其应用 |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| US10617667B2 (en) * | 2017-11-01 | 2020-04-14 | Ono Pharmaceutical Co., Ltd. | Method for treating brain tumors |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| WO2019149286A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US10973834B2 (en) * | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020014465A1 (en) | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020081979A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Low dose radiation conditioning for immunotherapy |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| JP7488269B2 (ja) * | 2019-01-22 | 2024-05-21 | キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド | Ｐｇｅ２／ｅｐ４シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用 |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020243390A1 (en) * | 2019-05-31 | 2020-12-03 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CN114729051A (zh) * | 2019-11-21 | 2022-07-08 | 百济神州(北京)生物科技有限公司 | 使用抗ox40抗体与放射组合治疗癌症的方法 |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| BR112022017382A2 (pt) * | 2020-03-04 | 2022-11-29 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| EP4286371A4 (en) * | 2021-01-28 | 2025-01-08 | Shenzhen Zhongge Biological Technology Co., Ltd. | Pyrazolamide derivative, preparation method therefor, and application thereof |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN117651554A (zh) | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Mcl-1抑制剂与抗癌剂的组合 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024537564A (ja) * | 2021-09-03 | 2024-10-11 | 武漢人福創新薬物研発中心有限公司 | Ｅｐ４拮抗剤化合物及びその塩、結晶多形並びに使用 |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| WO2023125724A1 (zh) * | 2021-12-30 | 2023-07-06 | 杭州阿诺生物医药科技有限公司 | 一种固体药物组合物 |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20050176696A1 (en) * | 2003-12-08 | 2005-08-11 | Regents Of The University Of Arizona | Synergistic anit-cancer compounds |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| ES2421453T3 (es) * | 2006-08-11 | 2013-09-02 | Merck Frosst Canada Ltd | Derivados de tiofenocarboxamida como ligandos del receptor EP4 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8921391B2 (en) * | 2009-04-22 | 2014-12-30 | Raqualia Pharma Inc. | Selective EP4 receptor antagonistic substance for treatment of cancer |
| CA2775761C (en) | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| SMT201700008T1 (it) | 2010-09-21 | 2017-03-08 | Eisai R&D Man Co Ltd | Composizione farmaceutica |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| CN110354266A (zh) | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
-
2015
- 2015-05-21 CN CN201910572217.2A patent/CN110354266A/zh active Pending
- 2015-05-21 EP EP15726847.5A patent/EP3134085B1/en active Active
- 2015-05-21 CN CN201580039416.7A patent/CN106572993B/zh active Active
- 2015-05-21 KR KR1020167035808A patent/KR102535283B1/ko active Active
- 2015-05-21 SG SG11201609770TA patent/SG11201609770TA/en unknown
- 2015-05-21 MA MA039906A patent/MA39906A/fr unknown
- 2015-05-21 JP JP2016568918A patent/JP6787792B2/ja active Active
- 2015-05-21 RU RU2016150650A patent/RU2708374C2/ru active
- 2015-05-21 EP EP25174070.0A patent/EP4656246A2/en active Pending
- 2015-05-21 US US15/312,980 patent/US20170182003A1/en not_active Abandoned
- 2015-05-21 CA CA2949961A patent/CA2949961C/en active Active
- 2015-05-21 AU AU2015264102A patent/AU2015264102C1/en active Active
- 2015-05-21 MX MX2016015363A patent/MX393818B/es unknown
- 2015-05-21 WO PCT/US2015/031931 patent/WO2015179615A1/en not_active Ceased
-
2016
- 2016-11-20 IL IL249065A patent/IL249065A0/en active IP Right Grant
-
2020
- 2020-06-03 JP JP2020096807A patent/JP7562296B2/ja active Active
-
2021
- 2021-11-17 US US17/528,510 patent/US11707448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A5 (OSRAM) | ||
| JP2016533366A5 (OSRAM) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2017517506A5 (OSRAM) | ||
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| JP2016501221A5 (OSRAM) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2019532047A5 (OSRAM) | ||
| JP2018522858A5 (OSRAM) | ||
| JP2017510661A5 (OSRAM) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2015500225A5 (OSRAM) | ||
| JP2016041733A5 (OSRAM) | ||
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| JP2016536286A5 (OSRAM) | ||
| WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
| CY1116847T1 (el) | Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 | |
| JP2016528162A5 (OSRAM) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2019533651A5 (OSRAM) | ||
| JP2015502926A5 (OSRAM) | ||
| JP2019511550A5 (OSRAM) | ||
| JP2016519107A5 (OSRAM) | ||
| JP2019510075A5 (OSRAM) | ||
| RU2017112088A (ru) | Лечение неопластических заболеваний |